Certara (NASDAQ:CERT) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Certara (NASDAQ:CERT) from a hold rating to a strong-buy rating in a report issued on Tuesday,Zacks.com reports.

Other analysts have also recently issued research reports about the stock. Leerink Partners raised shares of Certara from a “market perform” rating to an “outperform” rating and set a $13.00 target price for the company in a research note on Tuesday. Rothschild & Co Redburn started coverage on Certara in a research note on Friday, November 21st. They set a “buy” rating and a $10.00 price objective for the company. Rothschild Redb upgraded Certara to a “strong-buy” rating in a research report on Friday, November 21st. Morgan Stanley lowered their price target on Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $12.58.

Certara Stock Up 1.9%

Certara stock opened at $9.67 on Tuesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The stock has a market capitalization of $1.54 billion, a PE ratio of 138.14 and a beta of 1.46. The business has a 50 day simple moving average of $9.16 and a 200-day simple moving average of $10.57. Certara has a 12 month low of $8.02 and a 12 month high of $15.69.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The firm had revenue of $104.62 million for the quarter, compared to analysts’ expectations of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.18%. During the same quarter last year, the company earned $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, analysts anticipate that Certara will post 0.28 EPS for the current fiscal year.

Institutional Trading of Certara

Several large investors have recently added to or reduced their stakes in CERT. Central Pacific Bank Trust Division raised its holdings in shares of Certara by 124.3% during the 4th quarter. Central Pacific Bank Trust Division now owns 15,792 shares of the company’s stock worth $139,000 after acquiring an additional 8,752 shares during the period. Kopion Asset Management LLC increased its position in Certara by 49.9% during the fourth quarter. Kopion Asset Management LLC now owns 982,710 shares of the company’s stock worth $8,658,000 after purchasing an additional 327,064 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new position in Certara during the third quarter worth about $2,844,000. Morningstar Investment Management LLC purchased a new position in Certara during the third quarter worth about $1,598,000. Finally, Wasatch Advisors LP boosted its holdings in Certara by 28.6% in the 3rd quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock valued at $212,608,000 after purchasing an additional 3,865,455 shares during the last quarter. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.